Sodium-glucose cotransporter (SGLT2) inhibitors: Adverse effects, limitations, and safety concerns
Humanities & Social Sciences Reviews · 22.06.2026 · 14 (1) · 199-203
DOI: 10.18510/hssr.2026.14124 ↗Kurz gefasst
Fachartikel in der Zeitschrift Humanities & Social Sciences Reviews, online erschienen am 22.06.2026. Verfasst von Katarzyna Dudzińska und 9 weiteren Autor:innen. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-SA 4.0).
Abstract (Originalsprache)
Research objective: The aim of this work is to review the adverse effects, limitations, and major safety concerns associated with sodium–glucose cotransporter-2 (SGLT2) inhibitors used in the treatment of type 2 diabetes mellitus, heart failure, and chronic kidney disease. Particular attention was given to complications affecting the urinary tract, kidneys, pancreas, skeletal system, and the risk of drug interactions and hypoglycemia. Methodology: This study is based on a narrative review using the PubMed database as the sole data source. Extracted data covered treatment protocols, injected substances, clinical outcomes, and reported adverse effects. Relevant studies evaluating the mechanisms, incidence, and clinical significance of adverse events were analyzed and compared. Main conclusions: The reviewed evidence indicates that SGLT2 inhibitors are generally well tolerated; however, they may increase the risk of genital fungal infections, volume depletion, and euglycemic diabetic ketoacidosis. Transient reductions in estimated glomerular filtration rate and potential electrolyte disturbances were also observed. Concerns regarding bone mineral density reduction, particularly with canagliflozin, remain inconsistent across studies. Clinically significant pharmacokinetic drug interactions appear uncommon, although concomitant use with diuretics, insulin, or sulfonylureas may increase the risk of adverse outcomes. Despite their proven cardioprotective and nephroprotective benefits, SGLT2 inhibitors require careful clinical monitoring, especially in patients at increased risk of dehydration, hypoglycemia, or renal impairment. Further long-term studies are needed to better characterize their safety profile. Application of the study: The findings may support clinicians in the safe prescribing and monitoring of SGLT2 inhibitors, helping to identify patients at increased risk of urinary, renal, metabolic, or skeletal complications and to individualize therapy in type 2 diabetes mellitus, heart failure, and chronic kidney disease. Originality/Novelty of the study: This review consolidates current evidence on the adverse effects, limitations, and safety concerns of SGLT2 inhibitors across multiple organ systems, highlighting areas of ongoing uncertainty — such as bone mineral density effects and drug interactions — and underscoring the need for further long-term safety studies.
Zitieren
APA
Dudzińska, K., Kaftan, A., Plenikowski, J., Kahsin, A., Kacprzak, S., Greluk, A., Żuk, J., Ciszewski, W., Jurewicz, A., & Plenikowska, Z. (2026). Sodium-glucose cotransporter (SGLT2) inhibitors: Adverse effects, limitations, and safety concerns. Humanities & Social Sciences Reviews, 14(1), 199-203. https://doi.org/10.18510/hssr.2026.14124
Vancouver
Dudzińska K, Kaftan A, Plenikowski J, Kahsin A, Kacprzak S, Greluk A, et al. Sodium-glucose cotransporter (SGLT2) inhibitors: Adverse effects, limitations, and safety concerns. Humanities & Social Sciences Reviews. 2026;14(1):199-203. doi:10.18510/hssr.2026.14124
BibTeX
@article{Dudziska2026,
author = {Dudzińska, Katarzyna and Kaftan, Adam and Plenikowski, Jan and Kahsin, Aleksander and Kacprzak, Sandra and Greluk, Aleksandra and Żuk, Jonasz and Ciszewski, Wojciech and Jurewicz, Alicja and Plenikowska, Zofia},
title = {Sodium-glucose cotransporter (SGLT2) inhibitors: Adverse effects, limitations, and safety concerns},
journal = {Humanities & Social Sciences Reviews},
year = {2026},
volume = {14},
number = {1},
pages = {199--203},
doi = {10.18510/hssr.2026.14124}
}
EUVIMED